Navigation Links
TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Date:12/10/2007

Final Data from Pivotal Study Presented at 49th American Society of

Hematology Meeting

FRAZER, Pa., Dec. 10 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that in a pivotal study of patients with indolent non-Hodgkin's lymphoma (NHL), whose disease has progressed during or following treatment with rituximab, TREANDA (bendamustine HCl) induced a high rate of response. TREANDA(R) is a novel investigational chemotherapy. According to the National Cancer Institute, an estimated 30,000 people in the United States will be diagnosed in 2007 with indolent NHL, a serious and slow growing cancer of the lymphatic system that is difficult to treat because patients are prone to relapse after treatment. The final data from this multicenter study were presented at the 49th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA [Poster # 505-I; Abstract #1351].

"The high response rate in this study suggest that bendamustine could offer substantial periods of remission to patients with indolent NHL whose cancer is progressing after treatment with rituximab," said Brad Kahl, MD, Associate Professor, Director Lymphoma Service, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, and the lead investigator of this study. "Because many patients with NHL eventually become resistant to treatment with rituximab and other therapies, new treatments are always required."

In this pivotal study of 100 patients with indolent NHL whose disease has progressed during or following treatment with rituximab, or a rituximab- containing regimen, as assessed by an independent radiological committee, 75 patients had a response. Of those patients who responded to treatment, 14 had a complete response and three had an unconfirmed complete response. The median duration of response was 9.2 months. Bendamustine demonstrated a manageable tolerability profile. As would be expected of a chemothera
'/>"/>

SOURCE Cephalon Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
2. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
3. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
7. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
8. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
9. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
10. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
11. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- Integrated Silicon Solution, Inc. (Nasdaq: ISSI ... solutions, today announced that it will host its earnings ... a.m. Pacific Time (10:00 a.m. Eastern Time) to discuss ... quarter ended June 30, 2014. To access ... a.m. Pacific time on July 24, 2014.  The participant ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the largest ... MiE America , Inc., a leading provider of Siemens ... a long-term agreement naming BC Technical as the authorized ... MiE and BC Technical announced today that ... establish BC Technical as the service and systems provider ...
(Date:7/10/2014)... July 10, 2014  Decision Resources Group finds ... disease (ID) specialists are willing to prescribe Durata,s ... for use as OPAT, approximately two-thirds of the ... to their hospital inpatients. However, our findings indicate ... are initiated on OPAT following hospital discharge, and ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
(Date:7/11/2014)... FRIDAY, July 11, 2014 (HealthDay News) -- Children ... greater risk for complications and potentially even death ... a new study. However, the Johns Hopkins ... "miniscule." The researchers analyzed data on nearly ... United States underwent over a 22-year period. ...
(Date:7/11/2014)... July 11, 2014 According to a ... Application Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, ... Industrial, Automotive & Transportation, Agriculture) & Geography - Global ... of Internet of Things market was worth $1029.5 Billion ... by 2020, at an estimated CAGR of 4.08% from ...
(Date:7/11/2014)... -- Researchers from The Miriam Hospital have found ... have significantly higher rates of smoking than those ... were less likely to attempt quitting than those ... not be sufficient for this population. The study ... of print in the American Journal of ...
(Date:7/11/2014)... Steven Reinberg HealthDay Reporter ... to protect children from the worldwide scourge of dengue fever ... While the vaccine only prevented dengue fever in 56 percent ... three shots, it protected more than 88 percent of them ... lead to hospitalization, and sometimes death. "This vaccine has ...
(Date:7/11/2014)... Last month Watkins Insurance Group introduced ... the agency as a specialist in insurance and bonding ... Bachelor’s Degree in Business Administration from Texas State University. ... manage everything from performance and payment bonds, license and ... needs for those in the asphalt supplier industry. In ...
Breaking Medicine News(10 mins):Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Miriam Hospital study examines smoking prevalence 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3
... Office-based, surgeon-performed, ultrasound-guided, fine needle aspiration (FNA) of head ... rate compared to the standard palpation technique, indicates new ... Head and Neck Surgery . FNA ... or masses. In this technique, a thin, hollow needle ...
... Spanish researchers determined that rats treated with recombinant ghrelin displayed ... reduced the amount of fibrogenic cells by 25% in the ... liver damage and reduced oxidative stress and inflammation in the ... the March issue of Hepatology , a journal of ...
... ... ... ... ...
... Survey ... ... an estimated 12 million Americans, yet according to a survey of 1,000 people conducted by ... and saw the benefits of undergoing genetic testing, close to 80 percent had never talked ...
... finds , SUNDAY, Feb. 28 (HealthDay News) -- Exposure to ... of developing asthma, researchers say. , "In an earlier study, ... endotoxin and allergens [mite and cockroach] in their day-care centers. ... cohort study, if infants from low-income families with high risk ...
... ... ... ... ...
Cached Medicine News:Health News:Office-based ultrasound-guided FNA superior in diagnosing head and neck lesions 2Health News:Ghrelin mitigates liver fibrosis in animal models; regulates human fibrosis 2Health News:Ghrelin mitigates liver fibrosis in animal models; regulates human fibrosis 3Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 2Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 3Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 4Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 5Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 6Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 7Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 8Health News:Genetic Disease Foundation Encourages Americans to Know Their Genes at KnowYourGenes.org in Observance of World Rare Disease Day 2Health News:Genetic Disease Foundation Encourages Americans to Know Their Genes at KnowYourGenes.org in Observance of World Rare Disease Day 3Health News:Genetic Disease Foundation Encourages Americans to Know Their Genes at KnowYourGenes.org in Observance of World Rare Disease Day 4Health News:Household Dirt Won't Raise Asthma Risk in Infants 2Health News:CareTech Solutions Honors Five Hospitals with Rising Star Awards 2Health News:CareTech Solutions Honors Five Hospitals with Rising Star Awards 3Health News:CareTech Solutions Honors Five Hospitals with Rising Star Awards 4Health News:CareTech Solutions Honors Five Hospitals with Rising Star Awards 5
The MACS VA_500 (variable atmosphere) is primarily for the study and isolation of microaerophilic organisms,including Campylobacter spp,Helicobacter pylori and other similarly fastdious organisms....
Lose the variability of anaerobic jars and step into the 21st century with the anaerobic workstation that provides the answer to the common problems associated with anaerobic microbiology....
... is the most versatile orthopedic/trauma ... designed for both lower body ... an integrated shoulder attachment. The ... operating table for your most ...
... With MARS, the operating theatre is ready for ... surgical fields. Its modern design allows a quick, ... The individual components are connected securely and sturdily ... system. And if there should ever be a ...
Medicine Products: